Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Assets (2016 - 2025)

Bio-Techne has reported Assets over the past 17 years, most recently at $2.5 billion for Q4 2025.

  • Quarterly results put Assets at $2.5 billion for Q4 2025, down 5.53% from a year ago — trailing twelve months through Dec 2025 was $2.5 billion (down 5.53% YoY), and the annual figure for FY2025 was $2.6 billion, down 5.4%.
  • Assets for Q4 2025 was $2.5 billion at Bio-Techne, roughly flat from $2.5 billion in the prior quarter.
  • Over the last five years, Assets for TECH hit a ceiling of $2.8 billion in Q3 2023 and a floor of $2.1 billion in Q1 2021.
  • Median Assets over the past 5 years was $2.5 billion (2025), compared with a mean of $2.5 billion.
  • Biggest five-year swings in Assets: increased 17.21% in 2023 and later decreased 7.67% in 2025.
  • Bio-Techne's Assets stood at $2.3 billion in 2021, then grew by 2.54% to $2.4 billion in 2022, then grew by 15.54% to $2.7 billion in 2023, then dropped by 2.21% to $2.7 billion in 2024, then decreased by 5.53% to $2.5 billion in 2025.
  • The last three reported values for Assets were $2.5 billion (Q4 2025), $2.5 billion (Q3 2025), and $2.6 billion (Q2 2025) per Business Quant data.